These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29648831)

  • 1. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
    Wang H; Wang Y; Guo W; Du B; Huang X; Wu R; Yang B; Lin X; Wu Y
    Drug Des Devel Ther; 2018; 12():1183-1193. PubMed ID: 29785088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
    Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
    Ni Z; Wang X; Zhang T; Jin RZ
    Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
    EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
    Chuang YC; Huang BY; Chang HW; Yang CN
    Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.
    Mathi GR; Kang CH; Lee HK; Achary R; Lee HY; Lee JY; Ha JD; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
    Eur J Med Chem; 2017 Jan; 126():536-549. PubMed ID: 27915169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
    He MY; Li WK; Meiler J; Zheng QC; Zhang HX
    Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
    Goyal S; Jamal S; Shanker A; Grover A
    J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
    Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
    Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
    Zhao Z; Bourne PE
    J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.
    Blakely CM; Riess JW
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1061-1075. PubMed ID: 31809604
    [No Abstract]   [Full Text] [Related]  

  • 18. TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
    Murray BW; Zhai D; Deng W; Zhang X; Ung J; Nguyen V; Zhang H; Barrera M; Parra A; Cowell J; Lee DJ; Aloysius H; Rogers E
    Mol Cancer Ther; 2021 Sep; 20(9):1499-1507. PubMed ID: 34158340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
    Li J; Huang Y; Wu M; Wu C; Li X; Bao J
    Sci Rep; 2018 Jul; 8(1):10664. PubMed ID: 30006516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.